Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,236.86 +751.94 (+1.15%) CMC Crypto 200
1,406.15 -11.73 (-0.83%)
GenSight Biologics S.A. (0RIM.L)
- Business Wire
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
PARIS, June 04, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024.
- Business Wire
GenSight Biologics Appoints William Monteith to its Board of Directors
PARIS, June 03, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of William Monteith to its Board of Directors. Mr. Monteith joined as an independent Director after existing Board members approved his nomination at the meeting on May 29, 2
- Business Wire
GenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext Paris
PARIS, May 07, 2024--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA
